DPP-4 inhibition improves glucose tolerance and increases insulin and GLP-1 responses to gastric glucose in association with normalized islet topography in mice with β-cell-specific overexpression of human islet amyloid polypeptide

Regulatory Peptides

Volumn 143, Issue 1-3, 2007, Pages 97-103

  Ahrén, Bo ^a   Winzell, Maria Sörhede ^a   Wierup, Nils ^b   Sundler, Frank ^b   Burkey, Bryan ^c   Hughes, Thomas E ^c  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

DPP 4; Glucose tolerance; Insulin secretion; Islet amyloid polypeptide; Mice; Vildagliptin

Indexed keywords

AMYLIN; DIPEPTIDYL PEPTIDASE IV; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; VILDAGLIPTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; FEMALE; GLUCOSE TOLERANCE; INSULIN RESPONSE; INTRAVENOUS GLUCOSE TOLERANCE TEST; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET ALPHA CELL; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TOPOGRAPHY; TRANSGENIC MOUSE; WILD TYPE;

ADAMANTANE; AMYLOID; ANIMALS; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; GLUCOSE TOLERANCE TEST; HUMANS; IMMUNOHISTOCHEMISTRY; INSULIN; INSULIN-SECRETING CELLS; ISLET AMYLOID POLYPEPTIDE; ISLETS OF LANGERHANS; MICE; MICE, TRANSGENIC; NITRILES; PYRROLIDINES;

ANIMALIA; MUS; RODENTIA;

EID: 34547673164     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.regpep.2007.03.008     Document Type: Article

References (33)

1. Deacon C.F., Ahrén B., and Holst J.J. Inhibitors of dipeptidyl peptidase IV: a novel approach to prevention and treatment of type 2 diabetes. Expert Opin Investig Drugs 13 (2004) 1091-1102
2. Ahrén B. Inhibition of dipeptidyl peptidase-4 (DPP-4) - a novel approach to treat type 2 diabetes. Curr Enzyme Inhib 1 (2005) 65-73
3. Barnett A. DPP-4 inhibitors and their potential role in the management of type 2 diabetes. Int J Clin Pract 60 (2006) 1454-1470
4. Ahrén B., Holst J.J., Mårtensson H., and Balkan B. Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice. Eur J Pharmacol 404 (2000) 39-45
5. Balkan B., Kwasnik L., Miserendino R., Holst J.J., and Li X. Inhibition of dipeptidyl peptidase IV with NVP DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats. Diabetologia 42 (1999) 1324-1331
6. Kvist Reimer M., Holst J.J., and Ahrén B. Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice. Eur J Endocrinol 146 (2002) 717-727
7. Pedersen R.A., White H.A., Schlenzig D., Pauly R.P., McIntosh C.H.S., and Dermuth H.U. Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide. Diabetes 47 (1998) 1253-1258
8. Ahrén B., Gomis R., Standl E., Mills D., and Schweizer A. Twelve-and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 27 (2004) 2874-2880
9. Ahrén B., Landin-Olsson M., Jansson P.A., Svensson M., Holmes D., and Schweizer A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 89 (2004) 2078-2084
10. Raz I., Hanefeld M., Xu L., Caria C., Williams-Herman D., and Khatami H. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 49 (2006) 2564-2571
11. Ahrén B., Sörhede Winzell M., Burkey B., and Hughes T.E. Beta-cell expression of a dominant-negative HNF-1α compromises the ability of inhibition of dipeptidyl peptidase-4 to elicit a long-term augmentation of insulin secretion in mice. Eur J Pharmacol 521 (2005) 164-168
12. Ahrén B., Oosterwijk C., Lips C.J.M., and Höppener J.W.M. Transgenic overexpression of human islet amyloid polypeptide inhibits insulin secretion and glucose elimination after gastric glucose gavage in mice. Diabetologia 41 (1998) 1374-1380
13. Hull R.L., Andrikopoulos S., Verchere B., Vidal J., Wang F., Cnop M., et al. Increased dietary fat promotes islet amyloid formation and β-cell secretory dysfunction in a transgenic mouse model of islet amyloid. Diabetes 52 (2003) 372-379
14. Ar'Rajab A., and Ahrén B. Effects of amidated rat islet amyloid polypeptide on glucose-stimulated insulin secretion in vivo and in vitro in rats. Eur J Pharmacol 192 (1991) 443-445
15. Degano P., Silvestre R.A., Salas M., Peiro E., and Marco J. Amylin inhibits glucose-induced insulin secretion in a dose-dependent manner. Study in the perfused rat pancreas. Regul Pept 43 (1993) 91-96
16. Fürnsinn C., Leuvenink H., Roden M., Novotny P., Schneider B., Rohac M., et al. Islet amyloid polypeptide inhibits insulin secretion in conscious rats. Am J Physiol 267 (1994) E300-E305
17. Höppener J.W.M., Ahrén B., and Lips C.J.M. Mechanisms of disease: islet amyloid and type 2 diabetes mellitus. N Engl J Med 343 (2000) 411-419
18. Ritzel R.A., Meier J.J., Lin C.Y., Veldhuis J.D., and Butler P.C. Human islet amyloid polypeptide oligomers disrupt cell coupling, induce apoptosis, and impair insulin secretion in isolated human islets. Diabetes 56 (2007) 65-71
19. Wong H.Y., Ahrén B., Lips C.J.M., Höppener J.W.M., and Sundler F. Postnatally disturbed pancreatic islet cell distribution in human islet amyloid polypeptide transgenic mice. Regul Pept 113 (2003) 89-94
20. Villhauer E.B., Brinkman J.A., Naderi G.B., Burkey B.N.F., Dunning B.E., Prasad K., et al. 1-[[(3-hydroxy-1-adamantyl) amino] acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem 46 (2003) 2774-2789
21. Verchere C.B., D'Alessio D.A., Palmiter R.D., Weir G.C., Bonner-Weir S., Baskin D.G., and Kahn S.E. Islet amyloid formation associated with hyperglycemia in transgenic mice with pancreatic beta cell expression of human islet amyloid polypeptide. Proc Natl Acad Sci U S A 93 (1996) 3492-3496
22. Andrikopoulos S., Verchere C.B., Terauchi Y., Kadowaki T., and Kahn S.E. β-Cell glucokinase deficiency and hyperglycemia are associated with reduced islet amyloid deposition in a mouse model of type 2 diabetes. Diabetes 49 (2000) 2056-2062
23. Persson K., Gingerich R.L., Nayak S., Wada K., Wada E., and Ahrén B. Reduced GLP-1 and insulin responses and glucose intolerance after gastric glucose in GRP receptor-deleted mice. Am J Physiol 279 (2000) E956-E962
24. Wierup N., Kuhar M., Nilsson B.O., Mulder H., Ekblad E., and Sundler F. Cocaine- and amphetamine-regulated transcript (CART) is expressed in several islet cell types during rat development. J Histochem Cytochem 52 (2004) 169-177
25. Sörhede Winzell M., and Ahrén B. The high-fat fed mouse: a model for studying mechanisms and treatment of impaired glucose tolerance and type 2 diabetes. Diabetes 53 suppl 3 (2004) S215-S219
26. Burkey B.F., Li X., Bolognese K.L., Balkan B., Mone M., Russell M., et al. Acute and chronic effects of the incretin enhancer vildagliptin in insulin-resistant rats. J Pharmacol Exp Ther 315 (2005) 688-695
27. Mika A., Stashiko M., Lubben T., Parham M., Adler A., Feenstra M., et al. Acute DPP IV inhibition minimizes glucose and insulin responses to a glucose challenge in a diabetic mouse. Diabetes 52 suppl 1 (2002) A350
28. Hagenfeldt-Johansson K.A., Herrera P.L., Wang H., Gjinovci A., Ishihara H., and Wollheim C.B. β-Cell-targeted expression of a dominant-negative hepatocyte nuclear factor-1α induces a maturity-onset diabetes of the young (MODY)3-like phenotype in transgenic mice. Endocrinology 142 (2001) 5311-5320
29. Mulder H., Ahrén B., and Sundler F. Differential expression of islet amyloid polypeptide (amylin) and insulin in experimental diabetes in rodents. Mol Cell Endocrinol 114 (1995) 101-109
30. Mulder H., Ahrén B., and Sundler F. Differential effect of insulin treatment on islet amyloid polypeptide (amylin) and insulin gene expression in streptozotocin-induced diabetes in rats. J Endocrinol 152 (1997) 495-501
31. Mari A., Sallas W.M., He Y.L., Watson C., Ligueros-Seylan M., Dunning B.E., et al. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab 90 (2005) 4888-4894
32. Hui H., Farilla L., Merkel P., and Perfetti R. The short half-life of glucagon-like peptide-1 in plasma does not reflect its long-lasting beneficial effects. Eur J Endocrinol 146 (2002) 863-869
33. Xu G., Stoffers D.A., Habener J.F., and Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 48 (1999) 2270-2276